Latest news
Jazz Pharma Expands Again in Epilepsy With $820M Actio Bio Acquisition - MedCity NewsMedCity News · Mon, 10 Aug 2026 22:02:41 GMTJazz Pharmaceuticals expands rare epilepsy pipeline with Actio Biosciences deal - European Pharmaceutical ReviewEuropean Pharmaceutical Review · Mon, 10 Aug 2026 16:17:36 GMTJazz to buy rare epilepsy drugmaker in potentially $1.3B deal - BioPharma DiveBioPharma Dive · Mon, 10 Aug 2026 16:06:35 GMTJazz expands epilepsy portfolio with buy of Actio Biosciences - The Pharma LetterThe Pharma Letter · Mon, 10 Aug 2026 15:16:17 GMTJazz bets on epilepsy treatment with up to $1.32 billion deal for Actio - ReutersReuters · Mon, 10 Aug 2026 15:11:12 GMTJazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline - BioSpaceBioSpace · Mon, 10 Aug 2026 14:55:28 GMTJazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion - pharmexec.compharmexec.com · Mon, 10 Aug 2026 14:22:59 GMTJazz moves on Actio Bio for up to USD 1.3b to enter KCNT1-driven epilepsy market - AllSciAllSci · Mon, 10 Aug 2026 13:57:16 GMT